Primary refractory hodgkin lymphoma and autologous stem cell transplantation: results of the single-center prospective study
- 作者: Petrova G.1, Melkova K.1, Chernyavskaya T.1, Gorbunova N.1, Afanas'ev B.2, Demina E.1, Kostrykina V.1, Doronin V.1
-
隶属关系:
- N.N. Blokhin Russian Cancer Research Center
- I.P. Pavlov St.Petersburg State Medical University
- 期: 卷 20, 编号 3 (2015)
- 页面: 4-11
- 栏目: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/40141
- DOI: https://doi.org/10.17816/onco40141
- ID: 40141
如何引用文章
全文:
详细
作者简介
Galina Petrova
N.N. Blokhin Russian Cancer Research Center
Email: galina_petrova@bk.ru
MD 115478, Moscow, Russian Federation
K. Melkova
N.N. Blokhin Russian Cancer Research Center115478, Moscow, Russian Federation
T. Chernyavskaya
N.N. Blokhin Russian Cancer Research Center115478, Moscow, Russian Federation
N. Gorbunova
N.N. Blokhin Russian Cancer Research Center115478, Moscow, Russian Federation
B. Afanas'ev
I.P. Pavlov St.Petersburg State Medical UniversityR.M. Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation 197022, St.Petersburg, Russian Federation
E. Demina
N.N. Blokhin Russian Cancer Research Center115478, Moscow, Russian Federation
V. Kostrykina
N.N. Blokhin Russian Cancer Research Center115478, Moscow, Russian Federation
V. Doronin
N.N. Blokhin Russian Cancer Research Center115478, Moscow, Russian Federation
参考
- Eichenauer D.A., Boll B., Diehl V. Pharmacotherapy of Hodgkin lymphoma: standard approaches and future perspectives. Expert Opin. Pharmacother. 2014; 15(8): 1139-51.
- Демина Е.А., Тумян Г.С., Трофимова О.П., Иванов С.М., Кондратьева Н.Е., Унукова Н.Е. и др. Лимфома Ходжкина: лечение больных неблагоприятной группы. Практическая онкология. 2007; 8(2): 82-9.
- Linch D.C., Winfield D., Goldstone A.H. Moir D., Hancock B., McMillan A. et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin’s disease: Results of a BNLI randomized trial. Lancet. 1993; 341(8852): 1051-4.
- Schmitz N., Pfistner B., Sextro M., Sieber M., Carella A.M., Haenel M. et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy requiring autologous haemopoietic stem cell transplantation for relapsed chemosensitive Hodgkin’s disease: A randomised trial. Lancet. 2002; 359(9323): 2065-71.
- Constans M., Sureda A., Terol M.J., Arranz R., Caballero M.D., Iriondo A. et al. Autologous stem cell transplantation for primary refractory Hodgkin’s disease: Results and clinical variables affecting outcome. Ann. Oncol. 2003; 14(5): 745-51.
- Passweg J.R., Baldomero H., Peters C., Gaspar H.B., Cesaro S., Dreger P. et al. Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplant. 2014; 49(6): 744-50.
- Castagna L., Carlo-Stella C., Mazza R., Santoro A. Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma. Mediterr. J. Hematol. Infect. Dis. 2015; 7(1): e2015015.
- Younes A., Gopal A.K., Smith S.E., Ansell S.M., Rosenblatt J.D., Savage K.J. et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J. Clin. Oncol. 2012; 30(18): 2183-9.
- Barlogie B., Jagannath S., Vesole D.H., Naucke S., Cheson B., Mattox S. et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997; 89(3): 789-93.
- Mills W., Chopra R., McMillan A., Pearce R., Linch D.C., Goldstone A.H. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. J. Clin. Oncol. 1995; 13(3): 588-95.
- Castagna L., Crocchiolo R., Giordano L., Bramanti S., Carlo-Stella C., Sarina B. et al. High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant. Bone Marrow Transplant. 2015; Jan 26. doi: 10.1038/bmt.2014.304. [Epub ahead of print]
- Cheson B.D., Horning S.J., Coiffier B., Shipp M.A., Fisher R.I., Connors J.M. et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J. Clin. Oncol. 1999; 17(4): 1244-53.
- Melkova K., Chernyavskaya T., Abdusalamov S., Grivtsova L., Tupitsyn N. Application of autologous stimulated bone marrow as a source of hematopoietic material for transplantation. Cell. Ther. Transplant. 2011; 3(12): 33.
- Ballestrero А., Clavio M., Ferrando F., Gonella R., Garuti A., Sessarego M. et al. High-dose chemotherapy with tandem autologous transplantation as part of the initial therapy for aggressive non-Hodgkin’s lymphoma. Int. J. Oncol. 2000; 17(5): 1007-13.
- Wilson W.H., Jain V, Bryant G., Cowan K.H., Carter C., Cottler-Fox M. et al. Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. J. Clin. Oncol. 1992; 10(11): 1712-22.
- Абдусаламов С.Н., Мелкова К.Н., Горбунова Н.В., Чернявская Т.З. Профилактические режимы ведения больных и подходы к оптимизации сопроводительной терапии при трансплантации костного мозга. Клиническая онкогематология. 2010; 3(1): 21-9.